Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears

MUHAMMET KAZIM EROL1, OZDEMIR OZDEMIR2, DENIZ TURGUT COBAN1, BAŞAK BOSTANCI ČERAN1, ESİN SOĞUTLU SARI2

ABSTRACT

Purpose: To report the anatomical and visual results in patients diagnosed as having retinal pigment epithelium (RPE) tears after receiving ranibizumab injections.

Methods: Eyes diagnosed as having RPE tears with a minimum 6-month follow-up were retrospectively evaluated. Each eye was treated with at least three doses of ranibizumab at monthly intervals. Best-corrected visual acuity (BCVA), anterior segment findings, intraocular pressure, and fundus examination results were evaluated during control visits. Color fundus photography, fundus fluorescein angiographies, and spectral domain optical coherence tomography (SD-OCT) images were obtained. The height of pigment epithelial detachment (PED) was measured by SD-OCT.

Results: Twelve eyes with RPE tears were studied. Nine eyes (75%) developed RPE tears during ranibizumab injections for choroidal neovascularization (eight eyes with vascularized PED and one eye with choroidal osteoma), and tears occurred in three eyes before any injections. The median number of ranibizumab injections after diagnosis of RPE tears was 3 (min 2, max 5). In the most recent follow-up visit, there was no statistically significant correlation between the grade of RPE and logMAR of BCVA (p>0.05, r=0.112). Eight of twelve eyes had PED, and seven of these had irregular PED contours before injection therapy. The mean PED height was 447 ± 122 µm.

Conclusions: In this series, RPE tears developed mostly after intravitreal anti-VEGF injections. Increased vertical height and irregular contours of the PEDs can be risk factors for the formation of RPE tears. The continuation of anti-VEGF therapy after tear formation is beneficial for vision improvement in eyes with RPE tears.

Keywords: Macular degeneration; Retinal detachment; Retinal pigment epithelium; Intravitreal injections; Antibodies, monoclonal, humanized; Tomography, optical coherence; Vascular endothelial growth factor; Fluorescein angiography

INTRODUCTION

Retinal pigment epithelium (RPE) tear is a rare devastating complication of age-related macular degeneration (AMD). An RPE tear develops when the pigment epithelium detaches from the neurosensory layer with its basement membrane and retracts. RPE tears may develop spontaneously in eyes with AMD or after photocoagulation and photodynamic therapy. There are also cases reported to occur after Nd:YAG laser capsulotomy and cataract surgery. After anti-vascular endothelial growth factor (VEGF) therapies became widely used for choroidal neovascularization, the incidence of RPE tears has increased recently. Some authors have stated that the contraction of choriocapillaris lying beneath the RPE after anti-VEGF injection causes this complication. RPE tears are diagnosed by clinical examination, fluorescein angiography, optical coherence tomography (OCT), and fundus autofluorescence imaging of the macula. RPE tears have a characteristic appea-
rformance on fluorescein angiography. During fluorescein angiography, the bare area is hyperfluorescent in the early phase and leakage does not occur, unlike choroidal neovascularization. The scrolled region of the RPE is particularly dark and blocks the underlying fluorescence. On occasion, the scrolled area of the RPE has been termed ‘doubly hypofluorescent’. OCT scans through the retracted RPE show a very intense hyperreflectivity. A deep hyperreflectivity under the line corresponding to the RPE is evident in the area of the bare choroid. Fundus autofluorescence shows patchy or hazy hyperfluorescence.

The incidence of RPE tear formation following anti-VEGF treatment has been reported to range between 1.8% and 27% in recent studies. Different treatment protocols and follow-up periods may explain the wide incidence range and difficulties in diagnosing RPE tears. In previous case studies, the spontaneous healing of RPE tears has been demonstrated by using time-domain OCT. In a study conducted by Caramoy et al., the use of anti-VEGFs was proposed to slow down the scarring process, prevent photoreceptor damage, and give RPE a chance to heal. In this study, we evaluated the anatomical and visual results in patients diagnosed as having RPE tears after receiving ranibizumab injections as anti-VEGF treatment.

METHODS

The charts of 12 eyes of 12 choroidal neovascularization patients with at least 6 months follow-up after being diagnosed with RPE tears were retrospectively evaluated. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. All patients signed an informed consent form before undergoing any treatment.

Full ophthalmic examination, including best-corrected visual acuity (BCVA), anterior segment, and fundus and intraocular pressure were evaluated at the initial visit. Spectral domain (SD)-OCT was taken by using a Cirrus HD-OCT (Carl Zeiss Meditec Inc., Germany). The height of pigment epithelial detachment (PED) was evaluated by using SD-OCT, as previously described by Chan et al. Fundus photos, fundus autofluorescence images, and fundus fluorescein angiographies of the eyes were obtained by using a Visucam NM/FA fundus camera (Carl Zeiss, Dublin, California) in 45° mode.

In our clinic, patients diagnosed with choroidal neovascularization were treated with intravitreal ranibizumab (Lucentis, Genentech Inc., San Francisco, CA, USA) injections (0.5 mg/0.5 ml) at monthly intervals for the first 3-month period. After the third injection, eyes with more than a 50-μm increase in central foveal thickness and/or one or more lines of visual acuity loss on a Snellen chart receive repeated injections. This treatment protocol was not changed for patients who developed RPE tears during ranibizumab therapy.

RPE tears were graded as described by Sarraf et al. The grading was performed on the basis of the greatest length of a defect in the foveal direction of the tear and foveal involvement by using fluorescein angiographic analysis. Grade 1 tears (diameter <200 µm), Grade 2 tears (diameter between 200 µm and 1 disc diameter), Grade 3 tears (diameter >1-disc diameter), and Grade 4 tears (Grade 3 tears that involved the foveal center).

STATISTICAL ANALYSIS

Statistical analysis was performed by using a computer program (SPSS 18.0; SPSS Inc., Chicago, IL, USA). Results are reported as the mean ± standard deviation (SD), median, minimum (min), maximum (max), frequency, or percentage. BCVA results were converted to logMAR for statistical evaluation. The Wilcoxon signed rank t-test was used for comparisons. The correlations between the grade of the RPE tear and BCVAs in the first and last follow-ups were assessed by using Spearman’s rank correlation coefficient. A p value of <0.05 and an r value of >0.5 were considered to indicate statistical significance.

RESULTS

Twelve eyes of 12 patients were diagnosed as having RPE tears. The demographic properties of the patients are shown in table 1. Seven (58%) of the 12 patients were females. The mean age of the patients was 68.5 ± 14.5 years. Nine eyes (75%) developed RPE tears during ranibizumab injections. The median number of ranibizumab injections before RPE tears for nine eyes was 2 (min 1, max 3). Eight of the nine eyes with RPE tears had choroidal neovascularization with vascularized PED secondary to AMD, and the other one had choroidal neovascularization secondary to choroidal osteoma. The other three eyes with RPE tears were referred to our clinic from another hospital. Therefore, it was unknown whether PED existed before RPE tear formation. The patient histories of these patients showed that there were developments of choroidal neovascularization after cataract surgery (in one eye 15 days later and in two eyes 1 year later).

The mean follow-up time after the diagnosis of RPE tears was 12.1 ± 4.9 months. The median ranibizumab injection after the diagnosis of RPE tears was 3 (min 2, max 5). In all of the patients, ranibizumab was used as an anti-VEGF treatment agent. In the last follow-up visit, the BCVAs of the patients (logMAR 0.60 ± 0.52) were better than

Table 1. Characteristics, best-corrected visual acuity, grade of RPE tears, and numbers of ranibizumab injections of the patients

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Age</th>
<th>Sex</th>
<th>First BCVA (logMAR)</th>
<th>Last BCVA (logMAR)</th>
<th>Grade of RPE tear</th>
<th>Number of ranibizumab injections before RPE tear</th>
<th>Number of ranibizumab injections after RPE tear</th>
<th>Mean PED height (micron)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>72</td>
<td>M</td>
<td>1.0</td>
<td>0.1</td>
<td>1</td>
<td>0</td>
<td>4</td>
<td>No PED</td>
</tr>
<tr>
<td>2</td>
<td>76</td>
<td>F</td>
<td>0.2</td>
<td>0.1</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>344</td>
</tr>
<tr>
<td>3</td>
<td>57</td>
<td>M</td>
<td>0.3</td>
<td>0.1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>387</td>
</tr>
<tr>
<td>4</td>
<td>71</td>
<td>F</td>
<td>0.7</td>
<td>0.5</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>402</td>
</tr>
<tr>
<td>5</td>
<td>75</td>
<td>F</td>
<td>0.7</td>
<td>0.7</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>498</td>
</tr>
<tr>
<td>6</td>
<td>70</td>
<td>F</td>
<td>1.8</td>
<td>1.3</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>689</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>M</td>
<td>0.7</td>
<td>0.4</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>No PED</td>
</tr>
<tr>
<td>8</td>
<td>75</td>
<td>F</td>
<td>0.7</td>
<td>1.3</td>
<td>4</td>
<td>0</td>
<td>5</td>
<td>No PED</td>
</tr>
<tr>
<td>9</td>
<td>74</td>
<td>M</td>
<td>0.4</td>
<td>0.4</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>230</td>
</tr>
<tr>
<td>10</td>
<td>29</td>
<td>F</td>
<td>1.0</td>
<td>0.7</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>No PED</td>
</tr>
<tr>
<td>11</td>
<td>68</td>
<td>F</td>
<td>1.0</td>
<td>0.7</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>455</td>
</tr>
<tr>
<td>12</td>
<td>81</td>
<td>M</td>
<td>2.0</td>
<td>0.9</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>578</td>
</tr>
</tbody>
</table>

M = male; F = female; BCVA = best-corrected visual acuity; RPE = retinal pigment epithelium; PED = pigment epithelial detachment.
those at the first follow-up visit (logMAR 0.85 ± 0.45); however, the difference was not statistically significant (p=0.12). The median grade of the RPE tears was 2.5 (range, 1-4). In the last follow-up visit, there was a positive correlation between the RPE grade and logMAR BCVA, but the correlation was not statistically significant (p>0.05, r=0.112).

In five of the nine eyes that developed RPE tears during ranibizumab therapy, subretinal hemorrhages were evident. Five of these eyes developed RPE tears after the second injection, and two eyes hemorrhaged after the first dose. After tear development, hemorrhage was observed in only two eyes.

During the follow-up period, the RPEs (one Grade 1 and one Grade 2) in two eyes reattached. In these eyes, reattachments of RPE tears were observed by using SD-OCT and fundus autofluorescence imaging. Initially, the RPE tear areas were hypoautofluorescent and the tear borders were hyperautofluorescent. However, in the last visit, it was observed in two eyes that the hypoautofluorescence initially observed in the tear area had changed to hyperautofluorescence, and in one of the eyes, hyperautofluorescent spots were still evident in the hypoautofluorescent area. Eight of the twelve eyes with RPE tears had PED. The mean PED height of the eight eyes was 447 ± 122 µm initially. The PEDs of seven of these eyes had irregular contours.

**Representative case examples**

Case 3: A 57-year-old man was admitted to our clinic with vision loss in the left eye. The BCVA in the left eye was 1.0 logMAR. On the basis of the OCT and fundus fluorescein angiography findings, he was diagnosed with AMD, and an intravitreal ranibizumab treatment protocol was started. When his BCVA improved to 0.3 logMAR after the second dose, a Grade 2 RPE tear was observed in the inferior macula. Two doses of ranibizumab were administered after tear formation. Six months later, his BCVA improved to 0.1 logMAR. In fundus autofluorescence imaging, there was hyperautofluorescent spotting in the denuded RPE area, and subretinal and intraretinal hyper-reflective spots were seen in the OCT (Figure 1).

Case 9: A 74-year-old male was with vision loss in both eyes examined. His BCVA indicated the ability to count fingers at 1 m in the right eye and to count fingers at 2 m in the left eye. Fundus examination in the right eye revealed two disc-sized subretinal hemorrhages on the macula. He was diagnosed with AMD. After the second dose of ranibizumab, the subretinal hemorrhage was resorbed, BCVA increased to 0.4 logMAR (Figure 2 A), but OCT revealed an RPE tear (Figure 2 B). Three additional ranibizumab injections were administered after tear formation, and his BCVA remained stable at 0.4 logMAR (Figures 2 C and 2 D).

**DISCUSSION**

We observed that nine of the 12 eyes developed RPE tears during the treatment of choroidal neovascularization with ranibizumab injections. We continued to inject intravitreal ranibizumab after the development of RPE tears. After all injections, two of the 12 eyes appeared to be stable, nine of the 12 eyes showed improvement, and only one eye showed worsening of visual acuity at the end of the follow-up periods. At the last follow-up visits, however, the visual acuity had decreased in the patients with a high degree of tears, but the decrease was not statistically significant. According to our experience, continuation of anti-VEGF injections for patients who developed RPE tears during injection therapy appears to be necessary. In our study population, the heights of the PEDs were >400 microns, and PEDs in seven of the eight eyes had irregular contours.

The pathogenesis of RPE tears is not fully understood. Contraction of the choroidal neovascularization under the weak RPE, increased fluid transport secondary to exudative AMD under the RPE, globe deformation, vitreous syneresis, vitreous-macular traction due to vitreous incarceration in the injection hole, and detachment of the tight junctions between RPE cells are some of the mechanisms that have been considered. RPE tears usually develop from the temporal edge of the PED. The separated part of the RPE folds parallel to the PED and reveals the
bare Bruch’s membrane for a few days (2,8,12). After RPE tear formation, the PED usually becomes flat spontaneously. Reattachment of the free RPE edges to the Bruch membrane at a different location has recently been reported (2). There is a possibility of improvement in patients with lower grade RPE tears (12).

Overexpression of new tissue from the tear border provides solidity to the RPE layer. The intraretinal hyper-reflective spots in SD-OCT and the corresponding hyperfluorescent spots in fundus autofluorescence may be secondary to RPE migration (12). The existence of the hyperautofluorescent spots may be similar to the ones in central serous retinopathy (16). The reason for this is the corrupted pump mechanism in the RPE denuded region and phagocytosis in the outer segment. The hyperreflective spots in fundus autofluorescence imaging may represent the subretinal or intraretinal outer photoreceptor segments that are phagocytized by the macrophages because the photoreceptor cells can live up to 325 days in the RPE denuded area (12). Moreover, it has been demonstrated that the precipitates in the subretinal outer segment layer acted as hyperreflective spots in OCT ophthalmoscopy of central serous retinopathy (18,19).

Previous studies have reported repopulation and reattachment of RPE cells after tear formation, but these studies did not demonstrate healing of the hypoautofluorescence in the tear region (2,8,12). Pece et al. used OCT to show that reattachment of the margins of an RPE tear were healed by tissue remodeling and described how the disease can recur (2,8). In our study, reattachment of the RPE tear was demonstrated by using SD-OCT and fundus autofluorescence imaging only in 2 eyes. In addition, the hypoautofluorescent area in the tear region healed partially in one eye after 6 months. In another eye, hyperautofluorescent spots had appeared in the hypoautofluorescent area. Similarly, Caramoy et al. reported a case in which healing in the hypoautofluorescent area was observed after 2.5 years. In that study using SD-OCT, 7 (19.4%) of 36 eyes showed patchy or hazy hyperfluorescent areas in fundus autofluorescence imaging, and the majority of the eyes (83.3%) showed hyperreflective dots that possibly represented hard exudates and intraretinal RPE migration. The authors stated that fundus autofluorescence imaging showed a considerable amount of RPE proliferation, repopulation, and migration (12).

In a recent study that included 1298 AMD patients, the pooled rate of RPE tears was 1.8% in the 0.5-mg ranibizumab group, 3.0% in the 0.3-mg ranibizumab group, and 1.6% in the control group. Better visual acuity results were achieved with ranibizumab treatment versus control treatment in patients with RPE tears. Moreover, the potential benefit of continued ranibizumab therapy was suggested for patients with RPE tears secondary to neovascular AMD (21). Garg et al. reported that 15 eyes from 15 patients developed an RPE tear, which gave an incidence of 1.6% in 920 eyes with exudative AMD treated with intravitreal bevacizumab. Six of the 15 eyes were continued to be injected with bevacizumab/ranibizumab after tear development, and four of these six eyes showed visual improvement (21). The risk for RPE tear after bevacizumab injection in eyes with PED seems to be moderate. Weinberger et al. investigated RPE tears after intravitreal bevacizumab in 31 eyes with PED and observed RPE tears in four eyes without vision loss. The authors concluded that continuation of anti-VEGF injections for patients who develop RPE tears during injection therapy seems to be necessary (23).

In a few studies, certain factors, such as large PED diameter, vertical height, and subretinal fluid, have been associated with an increase in RPE tear rate (5,24). The contour of the PED is an important factor for predicting RPE tear formation risk. Moroz et al. retrospectively evaluated 24 consecutive patients with choroidal neovascular membrane associated with PED, and reported the development of RPE tears after the first injection in six patients. They described two typical patterns in the eyes, which developed tears. One pattern was multifocal wrinkles and waves with RPE elevations, and the second was step-like interruptions of the continuity of the RPE line (25). Knowing these risk factors is important for identifying eyes that are likely to develop this complication. The anatomical SD-OCT characteristics of a PED leading to RPE tear after anti-VEGF therapy has recently been descri-
bed by Nagiel et al. and has been prospectively described by Sarraf et al.26,27. Eyes with vascularized PEDs secondary to AMD have a risk for RPE tear following intravitreal anti-VEGF injection. Those authors explained that the contraction of neovascular tissue adhering to the undersurface of the RPE and rapid involution may cause a substantial contractile force that tears this already-strained tissue layer26. A baseline PED height > 550 µm, presence of a Grade 1 tear, and positive ring sign are high-risk factors for the subsequent development of an RPE tear27. In our study, the mean PED height of eyes with RPE tears was 447 µm. The PED area was detected in seven of eight eyes with PED.

One of the patients in our study had choroidal neovascularization secondary to choroidal osteoma. Choroidal osteomas may decalcify and cause degeneration in the underlying retina, including the RPE. In this patient, the RPE tear occurred between the decalcified and calcified regions, which can be explained by the fragility of the area caused by degeneration of the RPE28. The RPE tear mechanism may be different for choroidal neovascularization secondary to choroidal osteoma. Sen et al. demonstrated that multiple anti-VEGF injections caused Bruch membrane rupture in angiod streaks in which the Bruch membrane was calcified and brittle, as in choroidal osteoma29. To our knowledge, our case is the first choroidal osteoma case to show the development of an RPE tear after ranibizumab therapy.

The limitations of this study included the limited sample size, lack of a comparison with a control group, lack of standard etiological and anatomical classifications, short follow-up period, and retrospective design. On the other hand, this was a single-center study and the same technicians performed the fundus autoflourecescence imaging and SD-OCT, which may have helped to standardize the input. For distinguishing risk factors and mechanisms for RPE tear formation either spontaneously or after VEGF therapy, randomized studies in larger patient series are needed.

CONCLUSION

In our series, RPE tears developed mostly after intravitreal anti-VEGF injections administered to treat vascularized PED. The study results demonstrate that SD-OCT, along with fundus autoflourecescence imaging and SD-OCT, which may have helped to standardize the input. For distinguishing risk factors and mechanisms for RPE tear formation either spontaneously or after VEGF therapy, randomized studies in larger patient series are needed.

REFERENCES